Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jun 21, 2016; 22(23): 5406-5414
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5406
Table 2 Hazard ratios and 95% confidence intervals for the association between potential prognosis factors and gastric cancer
CharacteristicnDFS
OS
HR (95%CI)1P value1HR (95%CI)2P value2HR (95%CI)1P value1HR (95%CI)2P value2
Age< 0.001< 0.001< 0.001< 0.001
< 60 yr7921111
≥ 60 yr7721.58 (1.35-1.85)1.42 (1.18-1.71)1.60 (1.35-1.89)1.39 (1.15-1.70)
Gender0.6740.9920.9760.651
Female3871111
Male11770.96 (0.80-1.15)1.00 (0.82-1.23)1.00 (0.82-1.21)1.05 (0.85-1.30)
Minority0.3640.6000.5630.797
Han population15071111
Others570.81 (0.51-1.28)0.87 (0.52-1.46)0.87 (0.54-1.40)0.93 (0.55-1.59)
History of familial cancer0.3670.2950.6100.523
No11571111
Yes1571.12 (0.87-1.44)1.15 (0.89-1.48)1.07 (0.82-1.41)1.09 (0.83-1.44)
Tumor location< 0.0010.7430.0030.545
Cardia10071111
Non-cardia5571.34 (1.14-1.57)0.97 (0.81-1.16)1.29 (1.09-1.53)0.94 (0.78-1.14)
TNM stage
I376111
II3292.71 (1.92-3.83)< 0.0012.61 (1.76-3.87)< 0.0013.27 (2.21-4.83)< 0.0013.33 (2.14-5.18)< 0.001
III8596.25 (4.64-8.44)< 0.0016.50 (4.57-9.23)< 0.0017.58 (5.37-10.70)< 0.0018.70 (5.83-12.98)< 0.001
Tumor embolus< 0.0010.339< 0.0010.802
No11751111
Yes2891.81 (1.53-2.13)1.10 (0.90-1.34)1.70 (1.43-2.03)0.97 (0.79-1.20)
Neural invasion< 0.001< 0.001< 0.001< 0.001
No13341111
Yes2301.90 (1.57-2.30)1.51 (1.21-1.89)2.06 (1.69-2.52)1.68 (1.33-2.12)
Adjuvant chemotherapy0.0080.01510.0520.002
No6781111
Yes8861.24 (1.06-1.47)0.79 (0.65-0.95)1.19 (1.00-1.40)0.73 (0.60-0.90)
Adjuvant radiotherapy0.0080.4780.2540.667
No14621111
Yes1021.46 (1.10-1.93)1.11 (0.83-1.49)1.20 (0.88-1.64)0.93 (0.67-1.29)
HER20.5610.1050.8980.118
Negative (-)10151111
Positive (+)5490.95 (0.81-1.12)1.19 (0.96-1.46)0.99 (0.83-1.18)1.19 (0.96-1.48)